Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization

Archives of Ophthalmology

Volumn 114, Issue 6, 1996, Pages 677-688

  Wilkinson, C P ^b   Hawkins, Barbara S ^a   Javornik, Noreen B ^b   Marvin Newhouse, M ^b   Keller, Jean A ^b   Bressler, Neil M ^b   Bressler, Susan B ^b   Burgess, Dean B ^b   Fine, Stuart L ^b   Hiner, Cheryl J ^b   Maguire, Maureen C ^b   Orth, David H ^b  

^a MPS Coordinating Center ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLINDNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; OCULAR HISTOPLASMOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULOPATHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 8944223026     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1996.01100130669006     Document Type: Article

References (39)

1. Schlaegel TF, Weber JC. Follow-up study of presumed histoplasmosis choroiditis. Am J Ophthalmol. 1971;71:1192-1195.
2. Makley TA, Long JW, Suie T, Stephan JD. Presumed histoplasmic chorioretinitis with special emphasis on the present modes of therapy. Trans Am Acad Ophthalmol Otolaryngol. 1965;443-457.
3. Feman SS, Podgorski SF, Penn MK. Blindness from presumed ocular histoplasmosis in Tennessee. Ophthalmology. 1982;89:1295-1298.
4. Gass JDM, Wilkinson CP. Follow-up study of presumed ocular histoplasmosis. Trans Am Acad Ophthalmol Otolaryngol. 1972;76:672-694.
5. Macular Photocoagulation Study Group. Argon laser photocoagulation for ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1983;101:1347-1357.
6. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1987;105:1499-1507.
7. Van Metre TE, Maumenee AE. Specific ocular uveal lesions in patients with evidence of histoplasmosis. Arch Ophthalmol. 1964;71:314-324.
8. Ganley JP. Epidemiologic characteristics of presumed ocular histoplasmosis. Acta Ophthalmol. 1973;(suppl 119):1-63.
9. Gunby P. Ocular histoplasmosis. JAMA. 1980;243:626-627.
10. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109-1114. [Correction. 1992;110:761.]
11. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol. 1994;112:500-509.
12. Fine SL, Wood WJ, Isernhagen RD, et al. Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: results of a pilot randomized clinical trial. Arch Ophthalmol. 1993;111:19-20.
13. Lewis ML, Schiffman JC. Long-term lollow-up of the second eye in ocular histoplasmosis. Int Ophthalmol Clin. 1983;23:125-135.
14. Watzke RC, Claussen RW. The long-term course of multifocal choroiditis (presumed ocular histoplasmosis). Am J Ophthalmol. 1981;91:750-760.
15. Sawelson H, Goldberg RE, Annesley WH, Tomer TL. Presumed ocular histoplasmosis syndrome: the fellow eye. Arch Ophthalmol. 1976;94:221-224.
16. Macular Photocoagulation Study Group. MPS Manual of Procedures. Springfield, Va: National Technical Information Service; 1991. Accession No. PB91-159368.
17. Bailey IL, Lovie JE. New design principles for visual acuity letter charts. Am J Optom Physiol Optics. 1976;53:740-745.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Beyer WH, ed. Standard Probability and Statistics Tables and Formulae. Boca Raton, Fla: CRC Press; 1991:171.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
21. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972;135:185-206.
22. Cox DR. Regression models and life-tables [with discussion]. J R Stat Soc B. 1972;34:187-220.
23. SAS Institute Inc. SAS Technical Report P-217 SAS/STAT Software: The PHREG Procedure. Version 6. Cary, NC: SAS Institute Inc; 1991.
24. Hillis A, Maguire M, Hawkins BS, Newhouse MM. The Markov process as a general method for nonparametric analysis of right-censored medical data. J Chron Dis. 1986;39:595-604.
25. Hawkins BS, Ganley JP. Risk of visual impairment attributable to ocular histoplasmosis. Arch Ophthalmol. 1994;112:655-666.
26. Gutman FA. The natural course of active choroidal lesions in the presumed ocular histoplasmosis syndrome. Trans Am Ophthalmol Soc. 1979;77:515-541.
27. Ryan SJ. De novo subretinal neovascularization in the histoplasmosis syndrome. Arch Ophthalmol. 1976;94:321-327.
28. Wilkinson CP. Presumed ocular histoplasmosis. Am J Ophthalmol. 1976;82:140-142.
29. Miller SA, Stevens TS, De Venecia G. De novo lesions in presumed ocular histoplasmosis-like syndrome. Er J Ophthalmol. 1976;60:700-712.
30. Hiner CJ, Javornik NB, Maguire MG, Bressler NM. Retinal pigment epithelial changes preceding active choroidal neovascularization due to ocular histoplasmosis. Invest Ophthalmol Vis Sci. 1992;33(suppl):725. Abstract.
31. Gass JDM. Stereoscopic Atlas of Macular Diseases, Vol 1, Diagnosis and Treatment. St Louis, Mo: C. V. Mosby Company; 1987:112-128.
32. Smith RE, Dunn S, Jester JV. Natural history of experimental histoplasmic choroiditis in the primate, I: clinical features. Invest Ophthalmol Vis Sci. 1984;25: 801-809.
33. Smith RE, Dunn S, Jester JV. Natural history of experimental histoplasmic choroiditis in the primate, II: histopathologic features. Invest Ophthalmol Vis Sci. 1984;25:810-819.
34. Palvolgyi I, Anderson A, Rife L, et al. Immunopathology of reactivation of experimental ocular histoplasmosis. Exp Eye Res. 1993;57:169-175.
35. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol. 1993;111:1189-1199.
36. Orlando RG, Davidorf FH. Spontaneous recovery phenomenon in the pre-sumed ocular histoplasmosis syndrome. Int Ophthalmol Clin. 1983;23:137-149.
37. Jost BF, Olk RJ, Burgess DB. Factors related to spontaneous visual recovery in the ocular histoplasmosis syndrome. Retina. 1987;7:1-8.
38. Berger AS, Kaplan HJ. Clinical experience with the surgical removal of subfoveal neovascular membranes: short-term postoperative results. Ophthalmology. 1992;99:969-976.
39. Thomas MA, Dickinson JD, Melberg NS, et al. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994;101:1384-1396.